Scan-guided radiation for kidney cancer that has spread or returned
Tests scan-guided radiation in adults with spreading kidney cancer.
Plain-language title generated from the registry record
Registry title: CAIX PET/ CT Guided Radiation Therapy in CcRCC.
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with clear cell kidney cancer that has come back or spread. They start standard first-line drug treatment and have two PET/CT scans. Radiation is aimed at the visible tumour sites.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Clear cell renal cell carcinoma that has come back or spread, confirmed by tissue examination
- Earlier treatment
- Planned or ongoing first-line systemic therapy: targeted therapy plus anti-PD-1 immunotherapy
- Biomarker or test result
- Two PET/CT scans must be available: FDG PET/CT and a CAIX-targeted PET/CT
Main reasons for not taking part
- Cannot receive stereotactic radiotherapy as planned
- Uncontrolled serious illnesses or active infection
- Pregnant or breastfeeding
- Cannot or will not follow study procedures and follow-up
Read by machine on 12 November 2026.
Where in China
- Peking University First HospitalBeijing, ChinaContact: Ronghui YuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University First Hospital
- Trial code
- NCT07540260
- Record updated
- 20 April 2026
- Original description
This is a prospective, single-arm study in adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). Participants will receive standard systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) and undergo dual PET/CT imaging (FDG PET/CT and a CAIX-targeted PET/CT) to map disease sites. When feasible, PET/CT-visible lesions will be treated with image-guided stereotactic ablative radiotherapy (SABR). Patients will be followed to evaluate progression-free survival, local control of treated lesions, and treatment-related adverse events (planned enrollment: ~70).Read full original descriptionShow less
CAIX PET/ CT Guided Radiation Therapy in CcRCC.
This is a prospective, single-arm study in adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). Participants will receive standard systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) and undergo dual PET/CT imaging (FDG PET/CT and a CAIX-targeted PET/CT) to map disease sites. When feasible, PET/CT-visible lesions will be treated with image-guided stereotactic ablative radiotherapy (SABR). Patients will be followed to evaluate progression-free survival, local control of treated lesions, and treatment-related adverse events (planned enrollment: ~70).
Inclusion: Adults (≥18 years) Histologically confirmed clear cell renal cell carcinoma Recurrent or metastatic disease Planned or ongoing first-line systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) Dual PET/CT imaging available (FDG PET/CT and CAIX-targeted PET/CT) and eligible for radiotherapy planning Multidisciplinary assessment confirms radiotherapy is feasible to treat ≥75% of detectable lesions Able to provide written informed consent.
Exclusion: Unable to receive stereotactic radiotherapy as planned Uncontrolled serious comorbidities or active infection Pregnant or breastfeeding Unable or unwilling to comply with study procedures and follow-up.